Pulmonary responses to Bioweapon Category A Pathogens

描述（由申请人提供）：被认为是生物武器最大威胁的病原体包括炭疽杆菌、土拉热弗朗西斯菌和天花，它们都是CDC指定的A类病原体。作为生物武器，它们特别麻烦，因为它们使用肺部途径并产生异常难以诊断和治疗的疾病。此外，我们对这些病原体与肺部环境的相互作用知之甚少。可用的两种主要保护性选择是：1）开发诱导针对肺部感染的有效获得性免疫的疫苗和/或2）开发增强先天免疫的治疗剂。了解先天性和获得性免疫保护免受A类病原体肺部攻击的机制对于开发新的治疗方法至关重要。这些肺部生物威胁感染在自然界中的发病率都不足以让我们使用标准流行病学和统计分析来确定疗效。因此，我们必须高度依赖于良好表征的动物模型。我们已经建立了小鼠肺模型炭疽，毒力兔热病和牛痘病毒。我们与Lovelace呼吸研究所合作，以解决这些病原体与肺部的相互作用。项目和核心的项目领导人为本计划项目带来互补的专业知识，这将为所有项目及其目标提供重要的协同作用。项目1（Lipscomb）将使用定义的B。炭疽突变体，以研究主要毒力因子在吸入性炭疽的小鼠和非人灵长类动物模型中从肺传播和诱导终末器官损伤中的作用。它还将研究肺泡巨噬细胞和补体在防止传播中的作用。项目2（拾取）将解决负责保护免受肺部正痘病毒感染的宿主因素，并确定痘病毒辅助蛋白在肺部感染中的作用。项目3（里昂）将使用最近开发的LVS疫苗接种诱导的针对Biovar A F肺部感染的保护的小鼠模型。土拉热症，以确定负责保护的免疫机制。将在鼠模型中鉴定的保护机制与在气溶胶暴露的非人灵长类动物模型中鉴定的保护机制进行比较。与Macrogenics合作，我们将使用表达文库免疫来询问F。用于疫苗候选物的土拉热菌基因组。

DESCRIPTION (provided by applicant): Among the pathogens thought to represent the greatest threat as bioweapons are Bacillus anthracis, Francisella tularensis and smallpox, which are all CDC designated category A pathogens. As bioweapons they are particularly troublesome because they use the pulmonary route and produce diseases that are unusually difficult to diagnose and treat. Further, we know very little about the interaction of these pathogens with the lung environment. The two primary protective options available are: 1) development of vaccines that induce effective acquired immunity against lung infections and/or 2) development of therapeutics that enhance innate immunity. Understanding the mechanisms by which innate and acquired immunity protect against pulmonary challenge with category A pathogens is critical for developing new therapeutics. None of these pulmonary biothreat infections have a high enough incidence in nature to allow us to determine efficacy using standard epidemiological and statistical analysis. Therefore, we must rely heavily on well characterized animal models. We have developed murine pulmonary models for anthrax, virulent tularemia and cowpox virus. We have partnered with Lovelace Respiratory Research Institute to address the interactions of these pathogens with the lung. The Project Leaders of the projects and Cores bring complementary expertise to this Program Project that will provide significant synergy for all of the projects and their aims. Project 1 (Lipscomb) will use defined B. anthracis mutants to investigate the role of the primary virulence factors in dissemination from the lung and induction of end organ damage in murine and nonhuman primate models of inhalation anthrax. It will also investigate the role of alveolar macrophages and complement in preventing dissemination. Project 2 (Pickup) will address the host factors responsible for protection from a pulmonary orthopox virus infection and define the role of poxvirus accessory proteins in pulmonary infections. Project 3 (Lyons) will use a recently developed murine model of LVS vaccination induced protection against a pulmonary infection with Biovar A F. tularensis to define the immune mechanisms responsible for protection. Protective mechanisms identified in the murine model will be compared with those identified in an aerosol exposed nonhuman primate model. In partnership with Macrogenics, we will use Expression Library Immunization to interrogate the F. tularensis genome for vaccine candidates.